BE553356A - - Google Patents
Info
- Publication number
- BE553356A BE553356A BE553356DA BE553356A BE 553356 A BE553356 A BE 553356A BE 553356D A BE553356D A BE 553356DA BE 553356 A BE553356 A BE 553356A
- Authority
- BE
- Belgium
- Prior art keywords
- blood
- proteins
- water
- process according
- concentrate
- Prior art date
Links
- 210000004369 blood Anatomy 0.000 claims description 47
- 239000008280 blood Substances 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 42
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000012141 concentrate Substances 0.000 claims description 16
- 238000000502 dialysis Methods 0.000 claims description 12
- 239000012153 distilled water Substances 0.000 claims description 11
- 238000001556 precipitation Methods 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 7
- -1 aliphatic alcohols Chemical class 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 238000003307 slaughter Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 206010018910 Haemolysis Diseases 0.000 claims description 5
- 102000004142 Trypsin Human genes 0.000 claims description 5
- 108090000631 Trypsin Proteins 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 230000008588 hemolysis Effects 0.000 claims description 5
- 239000012588 trypsin Substances 0.000 claims description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 4
- 102000057297 Pepsin A Human genes 0.000 claims description 4
- 108090000284 Pepsin A Proteins 0.000 claims description 4
- 229940111202 pepsin Drugs 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 102000009123 Fibrin Human genes 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- 238000000751 protein extraction Methods 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 29
- 239000000126 substance Substances 0.000 description 14
- 230000029058 respiratory gaseous exchange Effects 0.000 description 13
- 239000013543 active substance Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 239000011149 active material Substances 0.000 description 6
- 244000309466 calf Species 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229920000298 Cellophane Polymers 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000000385 dialysis solution Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000002021 butanolic extract Substances 0.000 description 2
- 229930003836 cresol Natural products 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- AXZAYXJCENRGIM-UHFFFAOYSA-J dipotassium;tetrabromoplatinum(2-) Chemical compound [K+].[K+].[Br-].[Br-].[Br-].[Br-].[Pt+2] AXZAYXJCENRGIM-UHFFFAOYSA-J 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910001487 potassium perchlorate Inorganic materials 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- YLXIPWWIOISBDD-NDAAPVSOSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CNC[C@H](O)C1=CC=C(O)C(O)=C1 YLXIPWWIOISBDD-NDAAPVSOSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000603 anti-haemophilic effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE553356A true BE553356A (en, 2012) |
Family
ID=178194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE553356D BE553356A (en, 2012) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE553356A (en, 2012) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989006538A1 (en) * | 1988-01-13 | 1989-07-27 | Gebro Broschek Kg Pharmazeutische Fabrik | Process for producing a therapeutically active ingredient, in particular for cicatrization or for treatment in geriatry, and a therapeutic preparation containing said active ingredient |
-
0
- BE BE553356D patent/BE553356A/fr unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989006538A1 (en) * | 1988-01-13 | 1989-07-27 | Gebro Broschek Kg Pharmazeutische Fabrik | Process for producing a therapeutically active ingredient, in particular for cicatrization or for treatment in geriatry, and a therapeutic preparation containing said active ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1199597A (fr) | Procede de preparation industrielle de materiaux collageniques a partir de tissus placentaires humains, materiaux collageniques humains obtenus, leurs application comme biomateriaux | |
| CA1052307A (fr) | Procede d'extraction et de traitement de glycoproteines, de mucopolysaccharides et de substances qui les accompagnent | |
| FR2715405A1 (fr) | Procédé pour l'élimination des prions dans des collagènes et collagènes ainsi obtenus. | |
| FR2460138A1 (fr) | Preparation antithrombinique et son procede de fabrication | |
| FR2617488A1 (fr) | Procede de fabrication de structures organisees de collagene, notamment d'origine humaine, et structures organisees de collagene correspondantes | |
| FR2470148A1 (fr) | Procede de preparation de fibres solubles de collagene | |
| FR2540121A1 (fr) | Procede de preparation d'un facteur stimulant des colonies et de kallikreine provenant de l'urine humaine | |
| EP0402205A1 (fr) | Procédé de préparation de solutions d'albumine purifiée | |
| FR2527079A1 (fr) | Procede pour l'obtention, a partir de sang de veau, de substances actives accelerant la respiration cellulaire | |
| EP0237398B1 (fr) | Utilisation de polypeptides biologiquement actifs et compositions les contenants | |
| FR2714063A1 (fr) | Procédé de préparation de collagène à partir de cnidaires, et compositions obtenues utilisables en cosmétique. | |
| FR2495939A1 (fr) | Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies | |
| BE553356A (en, 2012) | ||
| EP0214035B1 (fr) | Nouvelles préparations de collagène placentaire, leur procédé d'extraction et leurs applications | |
| FR2654111A1 (fr) | Collagene, procede pour le preparer, et agent cosmetique le contenant. | |
| EP0354100B1 (fr) | Procédé de traitement de solutions protéiques contenant des pigments tels que, groupements héminiques ou chlorophylles en vue de leur décoloration et produits obtenus | |
| FR2522266A1 (fr) | Procede de preparation d'un agent fibrinolytiquement actif et agent obtenu | |
| US1469994A (en) | Extract obtainable from the mammalian pancreas or from the related glands in fishes, useful in the treatment of diabetes mellitus, and a method of preparing it | |
| JP5761661B2 (ja) | 海洋性腐植土の水溶性抽出液およびフルボ酸とその用途 | |
| CZ191098A3 (cs) | Způsob výroby hyaluronidázy a její použití | |
| FR2618303A1 (fr) | Preparation de gelatine presentant un degre bloom eleve a partir de sous-produits de volaille | |
| CN1020734C (zh) | 提取超氧化物歧化酶复合物的方法 | |
| EP0273780B1 (fr) | Procédé d'isolation de protides biologiquement actifs, stables en milieu acide | |
| FR2693208A1 (fr) | Procédé d'obtention d'une composition enzymatique d'origine végétale ainsi que composition obtenue par la mise en Óoeuvre de ce procédé. | |
| FR2667789A1 (fr) | Composition cicatrisante et procede pour sa preparation. |